# Teva Pharmaceutical Industries Limited share price today (Teva Pharmaceutical Industries Limited, TEVA)

> Teva Pharmaceutical Industries Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TEVA · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/teva

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $41.82 (+74.5% in a year)
- P/E: 98.0×, over 1 year
- Revenue (Jun 2026): $4.1 B (−0.8% on a year ago)
- Profit (Jun 2026): −$576 M (−304.3% on a year ago)
- Operating margin: 4.0% (−17.4 points on a year ago)
- ROE: 18%, FY25
- ROIC: 16.0%, against a 7.5% cost of capital: +8.5 points
- Profit that came in as cash: 134%, last 2 years

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Teva Pharmaceutical Industries Limited share price today? Teva Pharmaceutical Industries Limited's share price was $41.82 at the close on 4 November 2026. It has been rising for 50 weeks. That is 20.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $24 and $42, and at that close it sat 99% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row. Over the last 10 years the share price moved −18% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Teva Pharmaceutical Industries Limited pay? Teva Pharmaceutical Industries Limited pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Teva Pharmaceutical Industries Limited on? Teva Pharmaceutical Industries Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Teva Pharmaceutical Industries Limited profitable? Teva Pharmaceutical Industries Limited posted a net loss of $576 M in the Jun 2026 quarter. Full-year FY25 profit was $1.4 B. Over 4 years profit has grown 35.6% a year on average. That loss is 13.9% of the quarter's revenue. The same quarter a year earlier earned $282 M. 5 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$576 M, −304.3% on a year earlier. ## How much revenue does Teva Pharmaceutical Industries Limited make, and is it growing? Teva Pharmaceutical Industries Limited reported $4.1 B of revenue in the Jun 2026 quarter, −0.8% on the same quarter a year earlier. Over 4 years it has grown 2.1% a year on average. The last full year, FY25, came in at $17.3 B. The last four reported quarters add to $17.3 B. FY25 revenue was $17.3 B, +4.3% on the year before. Recent pace: the last four quarters grew +4.1% on average, against 2.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +4.1%, against +3.1% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Teva Pharmaceutical Industries Limited keep? Teva Pharmaceutical Industries Limited's operating margin was 4.0% in the Jun 2026 quarter, 17.4 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 17.8% and 22.9%. The latest quarter is below every full year in that period. Across 5 years it has been between 17.8% and 22.9%, and FY25's 22.9% is the highest of them. Why the margin moved: operating margin changed −17.4 percentage points on the year while gross margin changed +1.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Teva Pharmaceutical Industries Limited's profit turning into cash? Over the last 2 years, 134% of Teva Pharmaceutical Industries Limited's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $1.6 B of operating cash against $1.4 B of profit. After $501 M of spending on assets, $1.1 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Teva Pharmaceutical Industries Limited's cash go? Teva Pharmaceutical Industries Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.5 B on assets over the last 3 years. Averaged over those years that is 2.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.5 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Teva Pharmaceutical Industries Limited's P/E ratio, and how does it compare with its own history? Teva Pharmaceutical Industries Limited's P/E is 98.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Teva Pharmaceutical Industries Limited business getting better or worse? Teva Pharmaceutical Industries Limited's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Teva Pharmaceutical Industries Limited earn on its capital? Teva Pharmaceutical Industries Limited earned a ROE of 18% in FY25. That is up from a low of −29% in FY24. Its return on capital used (ROIC) is 8.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.2% net margin and 0.42× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 8.2% net margin × 0.42× asset turnover × 5.15× leverage (assets divided by equity) ≈ 17.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 16.0% − 7.5% = +8.5 percentage points. The 7.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 16.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 18.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Teva Pharmaceutical Industries Limited have too much debt? Teva Pharmaceutical Industries Limited has total debt of $16.9 B against shareholder equity of $7.8 B as of Jun 2026, so its debt is 2.18× its equity. Year by year, that ratio went from 2.10 in FY21 to 2.18 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Teva Pharmaceutical Industries Limited shareholding pattern? We have no ownership or short-position figures for Teva Pharmaceutical Industries Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 4.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Teva Pharmaceutical Industries Limited from balance-sheet trouble? For Teva Pharmaceutical Industries Limited, the Z-score is 0.68. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.68 is inside the danger zone, so the balance sheet is a real risk. ## How does Teva Pharmaceutical Industries Limited rank in its industry? 46.9 out of 100, rank 16 of 28 in Drug Manufacturers - Specialty & Generic, with 64% of the evidence available. Teva Pharmaceutical Industries Limited scores 46.9 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 16. Relative strength against the index is 16.9%, and revenue and profit growth are weak. The four parts add up to the total exactly: 13.6 + 10.3 + 9.8 + 13.2 = 46.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Teva Pharmaceutical Industries Limited compared with? Teva Pharmaceutical Industries Limited ranks 16 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 46.9 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 18.2/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 8.2/20 · Lead over its industry -5.3% · Lead over S&P 500 6.1% · 1 year 9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.1 + 18.2 + 13.8 + 8.2 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.8/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.3/20 · Lead over its industry -13.9% · Lead over S&P 500 -3.7% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.8 + 20.8 + 10.3 + 4.3 = 63.2 · What this means: Earnings are strong; relative strength in its sector is -13.9% and the one-year return is 15.8%. 3. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 12.2/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 16.8/20 · Lead over its industry 43.2% · Lead over S&P 500 59% · 1 year 150.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 12.2 + 9 + 16.8 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.9/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.8/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 17.1% · Lead over S&P 500 30.9% · 1 year 25.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.9 + 12.8 + 10.9 + 18.5 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.8/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.4/20 · Lead over its industry 18.3% · Lead over S&P 500 31.8% · 1 year 40.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.1 + 11.8 + 8.7 + 18.4 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 15.3/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.1/20 · Lead over its industry -19.8% · Lead over S&P 500 -10.4% · 1 year -9.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.4 + 15.3 + 11.8 + 7.1 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 15.1/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 12.8/20 · Lead over its industry 11.3% · Lead over S&P 500 23.9% · 1 year 75.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 15.1 + 9.3 + 12.8 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 3.6/20 · Lead over its industry -18% · Lead over S&P 500 -8.4% · 1 year 16.2% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.6 + 18.1 + 11 + 3.6 = 58.3 · What this means: Earnings are strong; relative strength in its sector is -18% and the one-year return is 16.2%. 9. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 55.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 100% · Profit n/a · Operating margin change 474.2 points · 62% evidence Capital efficiency 17.9/25 · ROCE 50.7% · Operating margin 49.8% · 76% evidence Valuation 9.2/20 · P/E 51.2× · PEG n/a · 15% evidence Relative strength 2.7/20 · Lead over its industry -19.6% · Lead over S&P 500 -10.2% · 1 year 81.6% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 17.9 + 9.2 + 2.7 = 55.8 · What this means: Earnings are strong; relative strength in its sector is -19.6% and the one-year return is 81.6%. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.3/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.4/20 · Lead over its industry -2.5% · Lead over S&P 500 8.9% · 1 year 35.5% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.5 + 20.3 + 9.2 + 11.4 = 55.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.4 out of 100 Growth Capital Valuation Relative
12. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.8 out of 100 Growth Capital Valuation Relative
13. [Pacira BioSciences, Inc.](https://www.sectoralpha.in/us/stocks/pcrx) PCRX · breaking out · Evidence leans up · 64% evidence 50.3 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans down · 64% evidence 48.3 out of 100 Growth Capital Valuation Relative
15. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 47.1 out of 100 Growth Capital Valuation Relative
16. Teva Pharmaceutical Industries Limited this page TEVA · leader · Evidence leans down · 64% evidence 46.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.6/35 · Revenue 4.1% · Profit n/a · Operating margin change -17.4 points · 62% evidence Capital efficiency 10.3/25 · ROCE 13.6% · Operating margin 4% · 76% evidence Valuation 9.8/20 · P/E 21.1× · PEG n/a · 15% evidence Relative strength 13.2/20 · Lead over its industry 4.8% · Lead over S&P 500 16.9% · 1 year 74.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.6 + 10.3 + 9.8 + 13.2 = 46.9 · What this means: Relative strength against the index is 16.9%, and revenue and profit growth are weak. 17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · basing · Too little evidence to rank firmly · 56% evidence 46.2 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.8 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 40.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · basing · Evidence leans down · 71% evidence 37.8 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.7 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.4 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 47.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · losing its lead · Too little evidence to rank firmly · 47% evidence 30.6 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Teva Pharmaceutical Industries Limited in size? Teva Pharmaceutical Industries Limited is the 2nd largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Takeda Pharmaceutical Company. Just below it: Haleon plc, Zoetis Inc., United Therapeutics Corporation, Viatris Inc. and Neurocrine Biosciences, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Takeda Pharmaceutical Company Limited](https://www.sectoralpha.in/us/stocks/tak) $66.4 billion
2. Teva Pharmaceutical Industries Limited $48.7 billion
3. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) $41.9 billion
4. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) $36.8 billion
5. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) $26.1 billion
6. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) $22.1 billion
7. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) $16.8 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Sea Limited](https://www.sectoralpha.in/us/stocks/se) $49.1 billion · Internet Retail
2. [Roper Technologies, Inc.](https://www.sectoralpha.in/us/stocks/rop) $48.8 billion · Software - Application
3. Teva Pharmaceutical Industries Limited $48.7 billion
4. [Workday, Inc.](https://www.sectoralpha.in/us/stocks/wday) $48.7 billion · Software - Application
5. [Keysight Technologies, Inc.](https://www.sectoralpha.in/us/stocks/keys) $48.7 billion · Scientific & Technical Instruments

## What else do people ask about Teva Pharmaceutical Industries Limited? ### What were Teva Pharmaceutical Industries Limited Limited's latest quarterly results? Teva Pharmaceutical Industries Limited reported revenue of $4.1 B and a net loss of $576 M for the Jun 2026 quarter. Revenue fell 0.8% and profit fell 304.3% compared with a year earlier. Earnings per share were −$0.49 (as of 4 November 2026). ### What is Teva Pharmaceutical Industries Limited Limited's market cap? Teva Pharmaceutical Industries Limited's market capitalisation is $48.7 B at a stock price of $41.82. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Teva Pharmaceutical Industries Limited Limited performing? Teva Pharmaceutical Industries Limited's share price has been rising for 50 weeks. In its latest quarter, revenue fell 0.8% and profit fell 304.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running (as of 4 November 2026). ### Will Teva Pharmaceutical Industries Limited Limited's stock price go up? This page does not forecast Teva Pharmaceutical Industries Limited's stock price. What it shows instead: the stock price is $41.82, and it has been rising for 50 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does Teva Pharmaceutical Industries Limited Limited have too much debt? Yes, Teva Pharmaceutical Industries Limited has a lot of debt: its debt is 2.13× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is Teva Pharmaceutical Industries Limited Limited in its business cycle? Teva Pharmaceutical Industries Limited's FY25 operating margin was 22.9%, against a 5-year range of 17.8% to 22.9%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 4.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Teva Pharmaceutical Industries Limited Limited story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Teva Pharmaceutical Industries Limited Limited a stock worth studying right now? What the numbers show: Teva Pharmaceutical Industries Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.